CCRM transforms scientific discoveries into impactful regenerative medicine ventures. Through its unmatched all-in-one commercialization model, CCRM provides value to academics by streamlining the path to market.

Transforming academic discoveries into market-ready ventures

CCRM actively sources innovative technologies through its expansive global network of partnering institutions under our technology-first company creation stream. With world-leading sector expertise and a commercialization track record, CCRM moves academic inventions to market through a proven process.

Built-in path to scalability

Our unique built-in path to scalability is valuable to companies in the Incubation Program because it reduces the high costs and complexity of scaling in cell and gene therapy, providing a seamless transition from innovation to market-ready commercialization that would otherwise be challenging to achieve independently. It involves:

Team: Trained staff of 240+

  • >60% with advanced degrees

Global networks: Academic, industry and investors

  • Access to complementary intellectual property (IP) through 200+ institutions
  • Global hubs expand footprint to three continents

Capital: Fully-funded de-risking, pre-seed/seed funding

  • 18 portfolio companies (2 exits)
  • 3 incorporated companies
  • CA >$1.2 B+ raised to date

Scalability: Established infrastructure and expertise

  • In-house R&D for wet diligence
  • 30,000 sq. ft. in-house process and analytical development and Good Manufacturing Practices (GMP) facility
  • Access to 115,000 sq. ft. CDMO subsidiary, OmniaBio Inc.

How the collaborative process behind CCRM’s Incubation Program works, from start to finish

Our incubation process starts by collaborating with academics to identify promising discoveries and technologies from their labs, assessing how CCRM’s ideas and innovations can provide value, and assisting in filing intellectual property (IP).

Screening and diligence are conducted, enabling visibility to emerging technology. We then complete fully-funded diligence, provide access to CCRM’s facilities and expertise, conduct indication scoping, and obtain guidance from CCRM’s global network of mentors.

Companies are incubated and grown by bundling with complementary IP, leading to new IP creation, the generation of feasibility data, and the business plan build. The process then involves seeking strategic partnerships and investors, as well as non-dilutive funding. This process results in the launch of a new advanced therapy venture.

CCRM provides support to ventures that graduate this process, building value post-transaction. Types of support include:

  • People: Access to technical expertise, and support with IP and finance and back office.
  • Facilities: Process development lab, Good Manufacturing Practices (GMP) facility, and office space.
  • Funding: Preferred rates, seed capital, and access to an investor network.